Filing Flows › Coya Therapeutics (COYA) › Q1 2026
Coya Therapeutics (COYA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Coya Therapeutics (COYA) reported revenue of $251K for the first quarter 2026 (Q1 2026), -3% from a year earlier and -94% from the quarter before.
Coya Therapeutics, Q1 2026: revenue $251K (-3% year over year), net loss $7.2M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $251K | -94% | -3% |
| Operating profit | −$7.6M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$6.2M | — | — |
What changed
Revenue was $251K in Q1 2026, down 3% year over year and down 94% from the previous quarter.
Operating costs exceeded revenue by $7.6M, an operating margin of -3042.1%. Total costs fell 1% while revenue fell 3%. The fastest-growing cost line was General & admin (+39%). The quarter ended with a net loss of $7.2M, wider than the previous quarter's $5.7M loss.
Operating cash flow was −$6.2M. Non-cash charges added back $3K of depreciation and $2.2M of share-based compensation. Working capital and other items used $1.2M.
Questions
What was Coya Therapeutics' revenue in the first quarter 2026?
Coya Therapeutics (COYA) reported revenue of $251K for the first quarter 2026 (Q1 2026), -3% from a year earlier and -94% from the quarter before.
Source: Coya Therapeutics 10-Q on SEC EDGAR.